Haleon plc (LON:HLN) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Haleon plc (LON:HLN) have earned a consensus rating of “Moderate Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is GBX 407.83.

HLN has been the topic of several analyst reports. Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 370 price objective on shares of Haleon in a research note on Friday, October 31st. JPMorgan Chase & Co. upped their price target on Haleon from GBX 315 to GBX 335 and gave the company an “underweight” rating in a research report on Wednesday, November 26th. Deutsche Bank Aktiengesellschaft dropped their price objective on Haleon from GBX 340 to GBX 335 and set a “buy” rating for the company in a research note on Thursday, January 22nd. Berenberg Bank boosted their target price on shares of Haleon from GBX 507 to GBX 517 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 450 target price on shares of Haleon in a report on Wednesday, January 21st.

Haleon Stock Performance

LON HLN opened at GBX 409.20 on Monday. Haleon has a twelve month low of GBX 325.10 and a twelve month high of GBX 419.50. The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 53.36. The stock has a market cap of £36.44 billion, a P/E ratio of 24.50, a PEG ratio of 1.49 and a beta of 0.19. The company’s 50-day simple moving average is GBX 375.13 and its 200 day simple moving average is GBX 362.08.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.